1098-97-1

Basic information

• Product Name: PYRITHIOXIN
• Synonyms: PYRITHIOXIN;PYRITHIOXINE;PYRITINOL;3,3’-(dithiobis(methylene))bis(5-hydroxy-6-methyl-4-pyridinemethano;3,3’-(dithiobis(methylene))bis(5-hydroxy-6-methyl-4-pyridinemethanol);3,3’-(dithiodimethylene)bis(5-hydroxy-6-methyl-4-pyridinemethano;biocefalin;bonol
• CAS NO: 1098-97-1
• Molecular Formula: C₁₆H₂₀N₂O₄S₂
• Molecular Weight: 368.47
• EINECS: 214-150-1
• Product Categories: API;Aromatics;Drug Analogues;Heterocycles;Intermediates & Fine Chemicals;Pharmaceuticals;Sulfur & Selenium Compounds;Inhibitors
• Mol File: 1098-97-1.mol
• Article Data: 2

Chemical Properties

• Melting Point: 218-220°
• Boiling Point: 742.787 °C at 760 mmHg
• Flash Point: 403.023 °C
• Appearance: COA
• Density: 1.448 g/cm³
• Storage Temp.: Keep in dark place,Inert atmosphere,Room temperature
• PKA: 9.31±0.10(Predicted)
• Merck: 14,7996
• CAS DataBase Reference: PYRITHIOXIN(CAS DataBase Reference)
• NIST Chemistry Reference: PYRITHIOXIN(1098-97-1)
• EPA Substance Registry System: PYRITHIOXIN(1098-97-1)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 26
• WGK Germany: 2
• RTECS: UT4836666
• Hazardous Substances Data: 1098-97-1(Hazardous Substances Data)

Usage

Uses

Different sources of media describe the Uses of 1098-97-1 differently. You can refer to the following data:
1. Pyritinol can be used as a nootropic used in the prevention and treatment of cerebrovascular diseases.
2. cognition enhancer, nootropic

Brand name

Biontabol;Bonifwn;Cefalogen;Cerebrotrofina;Cervitalin;Divalvon-d;Enbol;Encefort;Encerbrovit;Encerebron;Fulneurina;Geribolina;Gerontabol comp.;Juniormen;Leonar;Logos;Maind;Musa;Neuroxin;Piriditol;Piririomin;Piritinol;Piritiomin;Plenumil;Sawaxin;Scintidin;Tibased;Tomevit;Tonobrein;Tonomentis.

World Health Organization (WHO)

Pyritinol, which is claimed to promote the uptake of glucose in the brain, is used in the treatment of cerebrovascular disorders. However, WHO is not aware of controlled experimental data to show that it has any therapeutic effect.

InChI:InChI=1/C16H20N2O4S2/c1-9-15(21)13(5-19)11(3-17-9)7-23-24-8-12-4-18-10(2)16(22)14(12)6-20/h3-4,19-22H,5-8H2,1-2H3

Synthetic route

pyrithioxin dihydrochloride → Pyritinol (1098-97-1)

Conditions	Yield
With sodium carbonate In water	70%

triphenylborane (960-71-4) + Pyritinol (1098-97-1) → diphenylborinic acid 5,5'-dihydroxy-6,6'-dimethyl-3,3'-(2,3-dithia-butane-1,4-diyl)-bis-pyridin-4-ylmethyl ester (22638-93-3)

Conditions	Yield
In ethanol

benzoyl chloride (98-88-4) + Pyritinol (1098-97-1) → Bis[2-Methyl-3-Benzoyloxy-4-Benzoyloxymethyl-5-Pyridyl-methyl]Disulfide Dihydrochloride

Conditions	Yield
With hydrogenchloride In pyridine; chloroform

hypofluorous acid trifluoromethyl ester (373-91-1) + Pyritinol (1098-97-1) → bis[2-methyl-3-hydroxy-4-hydroxymethyl-6-ethoxy-5-pyridylmethyl]disulfide (55422-94-1)

Conditions	Yield
With trifluoroacetic acid In methanol; water

Upstream product

• 10049-83-9 pyrithioxin dihydrochloride 

Relevant articles and documents

Diarylmethylene disulfide compound as well as preparation method and application thereof

The invention relates to the technical field of medicines and in particular relates to a diarylmethylene disulfide compound as well as a preparation method and application thereof. An experiment result shows that on a cell model, the diarylmethylene disulfide compound provided by the invention has an effect of inhibiting neurotoxicity caused by excessive glutamic acid and an effect of inhibiting neurotoxicity caused by hydrogen peroxide; the diarylmethylene disulfide compound also has a platelet aggregation resisting effect and can be used for reducing a cerebral infarct area in a mouse MCAO (Middle Cerebral Artery Occlusion) model. The results show that the diarylmethylene disulfide compound provided by the invention can have prevention and/or treatment effects on cerebral stroke.